AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26115789
Drug: Previous stimulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous stimulant medication history
Trial: 29200411
Drug: Bicyclol 25
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicyclol 25 mg three times daily
Trial: 24081374
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (α-tocopherol) 100 mg three times daily
Trial: 11733660
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol-alfentanil
Trial: 27515095
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection (2.5 mL of bupivacaine, 2.5 mg of morphine and 1 mL of betamethasone, 6 mL of fluid injection)
Trial: 26686847
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg daily for 12 weeks)
Trial: 22710607
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day p.o.) plus gemcitabine (1000 mg/m2, days 1, 8, 15, every 4 weeks)
Trial: 20074372
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment (IST)
Trial: 15652874
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg/day)
Trial: 1340245
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration with rehydration salts
Trial: 6147285
Drug: loprazolam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loprazolam (1.0 mg)
Trial: 6147285
Drug: nitrazepam (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrazepam (5.0 mg)
Trial: 21124330
Drug: Benidipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine (2 mg/day increased to 8 mg/day)
Trial: 20649501
Drug: Cilnidipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (5 mg/day increased to 20 mg/day)
Trial: 17704024
Drug: Low lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lactose infant formula supplemented with added precooked rice (1.5 g/100mL) with probiotic, prebiotic, fiber and increased amounts of zinc+iron
Trial: 17704024
Drug: Low lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lactose infant formula with added precooked rice without the above active ingredient supplement
Trial: 15846251
Drug: GRD 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 180 mg evening dose
Trial: 15846251
Drug: GRD 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 360 mg evening dose
Trial: 15846251
Drug: GRD 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 360 mg morning dose
Trial: 15846251
Drug: GRD 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 420 mg evening dose
Trial: 15846251
Drug: GRD 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRD 360 mg evening dose vs GRD 360 mg morning dose
Trial: 15846251
Drug: All GRD
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All GRD doses
Trial: 3645177
Drug: Educational sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational sessions designed to teach students various aspects of oral health
Trial: 3645177
Drug: Oral examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral examination control (Group one)
Trial: 2551359
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (CVM for 6 cycles)
Trial: 2551359
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (NM)
Trial: 2551359
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (CVM for 6 cycles) among patients in complete remission
Trial: 2551359
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (NM) among patients in complete remission
Trial: 31752508
Drug: Interpersonal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal and social rhythm therapy (IPSRT) with cognitive remediation
Trial: 28701300
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion to the ileum (15 g, 235 kJ)
Trial: 28701300
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion to the duodenum (15 g, 235 kJ)
Trial: 28701300
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion to the ileum
Trial: 28701300
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion to the duodenum
Trial: 17993283
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg/day, 35 mg/week, 50 mg/week, 15 mg/day)
Trial: 8518603
Drug: Antiepileptic drug
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drug withdrawal
Trial: 8518603
Drug: Continued antiepileptic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued antiepileptic drug treatment
Trial: 31096264
Drug: THC (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (one pill, administered 2 hours before threat extinction learning)
Trial: 31096264
Drug: Placebo (PBO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO, administered 2 hours before threat extinction learning)
Trial: 25950418
Drug: Daily oropharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oropharyngeal exercises
Trial: 12852841
Drug: Loratadine (LOR)
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine (LOR) 20 mg
Trial: 9141231
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg atenolol per day (beta-blocker group)
Trial: 9141231
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg fosinopril per day alone (control group)
Trial: 7506156
Drug: Nimesulide 100mg
RxNorm normalized name: nimesulide 100 MG
DrugBank: Nimesulide (DB04743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100mg twice daily for three 10-day cycles
Trial: 7506156
Drug: Nimesulide 200mg
RxNorm normalized name: nimesulide 200 MG
DrugBank: Nimesulide (DB04743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 200mg twice daily via rectal route
Trial: 7506156
Drug: Ketoprofen 100mg
RxNorm normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100mg twice daily via rectal route
Trial: 2962418
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 17 beta‐estradiol cyclo‐octyl acetate (E2COA) and 0.15 mg desogestrel for 21 days, followed by 0.03 mg desogestrel for an additional 7 days in half the group
Trial: 2962418
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg desogestrel added during the fourth investigation week
Trial: 18492834
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (5 mL/d, mean intake 3.1 g/d (n‐3) LCPUFA)
Trial: 14578244
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.5 units/kg s.c.)
Trial: 14578244
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (0.5 IU/kg)
Trial: 8817416
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose radiotherapy with chemotherapy
Trial: 1386691
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation (causing a nearly 20% fall in FEV1)
Trial: 6405435
Drug: d‐Amp (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐Amp (10 mg)
Trial: 6405435
Drug: d‐Amp (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐Amp (20 mg)
Trial: 15297952
Drug: Foot and
RxNorm normalized name: Carrington Foot and Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot and hand massage (20 minutes, 5 minutes to each extremity) provided 1 to 4 hours after pain medication
Trial: 9566646
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg day[-1])
Trial: 9566646
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg day[-1]) + omega-3 fatty acids (4 g day[-1])
Trial: 9566646
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids (4 g day[-1])
Trial: 9360002
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg once a day)
Trial: 2037324
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine administered intrapleurally
Trial: 24631095
Drug: JE-CV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV and MMR vaccines administered concomitantly (Group 'Co-Ad')
Trial: 24631095
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine administered separately after JE-CV (Group 'MMR')
Trial: 24631095
Drug: JE-CV vaccine
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV vaccine administered separately before MMR (Group 'JE-CV')
Trial: 24631095
Drug: JE-CV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV and MMR vaccines administered separately 6 weeks apart (Groups 'JE-CV' and 'MMR')
Trial: 22691917
Drug: IV-administered acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-administered acetaminophen 30 mg/kg, administered at the end of surgery and thereafter twice at 8-hour intervals
Trial: 22691917
Drug: IV-administered acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-administered acetaminophen 30 mg/kg
Trial: 19585478
Drug: Spearmint tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spearmint tea (twice a day for 30 days)
Trial: 9767554
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg daily of oral, micronized estradiol
Trial: 30927124
Drug: Hemospray (TC-325)
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemospray (TC-325) with epinephrine injection
Trial: 30927124
Drug: Hemoclip with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoclip with epinephrine injection
Trial: 22210362
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy for 1 hour
Trial: 20810251
Drug: Drug increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug increase
Trial: 20810251
Drug: Drug interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug interventions identified by epileptologists
Trial: 15964564
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg, n=16)
Trial: 10482259
Drug: Campath‐1H monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath‐1H monoclonal antibody treatment
Trial: 8760782
Drug: Mometasone furoate,
RxNorm normalized name: Mometasone Furoate, 50 mcg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate, 200 micrograms once daily
Trial: 8760782
Drug: Beclomethasone dipropionate,
RxNorm normalized name: Beclomethasone Dipropionate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate, 200 micrograms twice daily (400 micrograms total dose)
Trial: 31384292
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (pain management, bronchodilator inhalers, oxygen support, mechanical ventilation if needed, pulmonary physical therapy)
Trial: 25683094
Drug: Oral salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral salt supplementation (113 mmol Na(+) and 112 mmol Cl(‐))
Trial: 25683094
Drug: Oral salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral salt supplementation
Trial: 23070151
Drug: IDX184 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 25 mg once daily for 3 days
Trial: 23070151
Drug: IDX184 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 50 mg once daily for 3 days
Trial: 23070151
Drug: IDX184 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 75 mg once daily for 3 days
Trial: 23070151
Drug: IDX184 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 100 mg once daily for 3 days
Trial: 17961729
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with autologous hematopoietic stem cell support (AHSCT)
Trial: 15674510
Drug: Landiolol 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 5 mg
Trial: 15674510
Drug: Landiolol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 10 mg
Trial: 2227553
Drug: Chemotherapy (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (3 additional courses)
Trial: 28087382
Drug: Egg rush
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg rush oral immunotherapy (ROIT) in ROIT1 group
Trial: 28087382
Drug: Egg rush
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg rush oral immunotherapy (ROIT) in ROIT2 group
Trial: 26043229
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype (common allele)
Trial: 23311856
Drug: Usual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual and Customary Therapy of Equivalent Dose (DEUCC)
Trial: 23311856
Drug: Usual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual and Customary Therapy (UCC)
Trial: 9060567
Drug: Sucralfate solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate solution, used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores.
Trial: 9060567
Drug: Placebo solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution, used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores.
Trial: 2868162
Drug: tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamoxifen 20 mg daily
Trial: 26476022
Drug: IV tPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tPA + endovascular therapy (Solitaire stent-retriever)
Trial: 19672742
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group II (oral compound calcium acid chelate, Vitamin AD guttate and ipriflavone)
Trial: 19672742
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group I (oral compound calcium acid chelate and Vitamin AD guttate)
Trial: 19672742
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo and compound calcium acid chelate)
Trial: 18782465
Drug: Simvastatin monotherapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin monotherapy (n = 229)
Trial: 16184721
Drug: Octreotide 0.1
RxNorm normalized name: octreotide 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.1 mg subcutaneously 3 times/day for 7 days
Trial: 8927315
Drug: Ciba Vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciba Vision AOSept Disinfection/Neutralization Solutions (AOSept)
Trial: 8927315
Drug: Opti‐Free Rinsing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opti‐Free Rinsing, Disinfection, and Storage Solution (Opti‐Free)
Trial: 8927315
Drug: ReNu Multi‐Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReNu Multi‐Purpose Solution (ReNu)
Trial: 6328637
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g daily in divided doses)
Trial: 31793630
Drug: Adalimumab combination
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab combination therapy (34 patients)
Trial: 31793630
Drug: Adalimumab monotherapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab monotherapy (44 patients)
Trial: 31793630
Drug: Adalimumab combination
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab combination therapy and monotherapy
Trial: 29056106
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary calcium (547 mg DC)
Trial: 29056106
Drug: High supplemental
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High supplemental calcium (500 mg SC-calcium carbonate)
Trial: 29056106
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium (42 mg DC)
Trial: 9630386
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (0.9 g total catechins)
Trial: 9630386
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (0.3 g total catechins)
Trial: 9630386
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea with milk (100 ml in 600 ml)
Trial: 3135784
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) at 120% of resting energy expenditure (REE) with 0.2 g of N/kg/d
Trial: 3135784
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) at 200% of resting energy expenditure (REE) with 0.33 g of N/kg/d
Trial: 31394274
Drug: Flu-based conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu-based conditioning (Flu1: Flu 120-150 mg/m2, Cy 120-200 mg/kg, ATG 20 mg/kg; Flu2: Flu 150 mg/m2, Cy 300 mg/m2, ATG 20 mg/kg)
Trial: 25050594
Drug: BDP/F‐HFA 100/6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/F‐HFA 100/6 μg pMDI
Trial: 25050594
Drug: Budesonide/formoterol 320/9 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 320/9 μg DPI
Trial: 25050594
Drug: Fluticasone/salmeterol 500/50 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/salmeterol 500/50 μg DPI
Trial: 19228428
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg once daily) plus inhaled formoterol (9 microg bid)
Trial: 16402915
Drug: Milrinone (n=15)
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone (n=15) infusion for 72 hours
Trial: 16402915
Drug: Dobutamine (n=14)
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dobutamine (n=14) infusion for 72 hours
Trial: 16402915
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with decompensated CHF before inotropic treatment
Trial: 8702068
Drug: Bionator treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionator treatment for an average of 18.7 months
Trial: 1233531
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage of perphenacine
Trial: 25443473
Drug: Treatment Burden
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Burden scale
Trial: 23136195
Drug: Rilotumumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (15 mg/kg) plus mitoxantrone and prednisone (MP)